News

Findings from a recent study analyzing patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer indicate that PFS gains observed in selected studies of PARP inhibitors may be worth...

Study findings indicate that the introduction of biosimilar bevacizumab-bvzr may provide substantial cost savings from the US payers’ perspective, allowing for the bevacizumab treatment to become accessible to more patients.

Findings from a real-world study suggest that using single-agent ibrutinib for relapsed/refractory CLL is safe and effective in routine clinical practice.

Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.

Fixed duration venetoclax plus obinutuzumab for 12 months is a cost-effective first-line treatment regimen for unfit patients with CLL.

Study findings highlight the differences in tolerability profiles, treatment adherence, and health economics between three available PARP inhibitors for ovarian cancer.

Study findings the importance of risk stratification and cardiovascular monitoring for patients with cancer receiving immune checkpoint inhibitor therapy.

Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve PFS for newly diagnosed MM, compared to maintenance alone.

Study findings suggest immune checkpoint inhibitors can be safely administered in older patients with cancer and produce similar survival outcomes as those observed in younger patients.

A real-world study suggests that cancer drugs without documented OS benefits are increasingly adopted in the health system, accounting for substantial spending.